Similar results regarding FLT3 mutational status and response to GO were obtained in adult AML patients from the MRC AML15 and NCRI AML16 trials, in which GO failed to demonstrate a clinical improvement in FLT3-ITD cases [49]. This evidence concerns the gene FLT3 and acute myeloid leukemia.